Neuland Laboratories Ltd. has expanded its manufacturing capabilities for synthetic peptides. The company offers peptide production using standard sequential chemical peptide syntheses and segment condensation strategies, employing solid phase peptide synthesis procedures, as well as solution phase methods for shorter length peptides, and segment condensation and ligation techniques for very long peptides.
M.K. “Mike” Anwer, Ph.D., vice president of R&D at Neuland Labs, said, “Neuland’s extensive experience in producing a variety of synthetic peptides parallels their increasing use as therapeutics and diagnostics, in antibody production and as research tools. Our expanded service provides rapid access to commercial quantities of affordable, high quality peptides from a company with a 27-year track record of consistently achieving the highest regulatory standards in global pharmaceutical production.”